search
Back to results

Cognitive Behavioral Therapy for Obesity

Primary Purpose

Obesity

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CBT
educational
Sponsored by
US Department of Veterans Affairs
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity focused on measuring obesity, CBT, Atypical antipsychotics, metabolic syndrome

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age 18 years and above
  2. Patients with diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder determined by assessment with chart review, currently taking at least one atypical antipsychotic, started at least 2 months prior to randomization
  3. Body Mass Index (BMI) greater than 30
  4. ability to consent to treatment, determined by the patient's treating/referring physician

Exclusion Criteria:

  1. Patients with premorbid medical problems that preclude involvement in a weight loss program
  2. Active substance abuse or dependence, indicated by a positive urine drug screen in the last 3 months
  3. Mini- Mental Status Exam (MMSE) less than 24
  4. active psychosis or mania, determined by administration of the PANSS score greater than 3 on the following items; delusions, conceptual disorganization, hallucinatory behavior, blunted affect, social withdrawal, lack of spontaneity and conversation flow, mannerisms and posturing, and unusual thought content, and YMRS greater than 10, respectively
  5. active major depressive episode, determined by administration of HAM-D greater than 13
  6. patients taking any medications for weight loss or currently enrolled in a weight loss program
  7. changes in medication regimen for diabetes or dyslipidemia within the last 3 months

Sites / Locations

  • Michael E. DeBakey VA Medical Center (152)

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

1

2

Arm Description

6-CBT-sessions for weight loss

Single educational intervention for weight

Outcomes

Primary Outcome Measures

The accessibility to overweight outpatients with stable psychotic or mood disorders, currently treated with atypical antipsychotics willing to participate in a research study involving CBT.

Secondary Outcome Measures

Measure outcome parameters; body mass index, total cholesterol, low-density lipoproteins, triglycerides, fasting blood sugar, waist circumference, blood pressure & pulse among patients receiving CBT treatment or usual care at baseline, 6 wks & 12 wks.

Full Information

First Posted
December 5, 2007
Last Updated
March 19, 2009
Sponsor
US Department of Veterans Affairs
search

1. Study Identification

Unique Protocol Identification Number
NCT00569517
Brief Title
Cognitive Behavioral Therapy for Obesity
Official Title
The Effect of Brief Group Cognitive Behavioral Therapy on Decreasing Metabolic Syndrome Risk Factors in Obese Patients Treated With Atypical Antipsychotics
Study Type
Interventional

2. Study Status

Record Verification Date
March 2009
Overall Recruitment Status
Completed
Study Start Date
January 2008 (undefined)
Primary Completion Date
December 2008 (Actual)
Study Completion Date
March 2009 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
US Department of Veterans Affairs

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this pilot study is to assess patient accessibility, interest and response in order to design an adequately powered study to compare brief, group cognitive behavioral therapy (CBT) for weight loss to usual care in non-demented patients above the age of 18 years old who are currently taking atypical antipsychotic medications. This pilot study is necessary, with current limitations of data in this area, to design an adequately powered study to address the difficulties managing metabolic syndrome risk factors in patients on antipsychotics.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity
Keywords
obesity, CBT, Atypical antipsychotics, metabolic syndrome

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
32 (Actual)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Experimental
Arm Description
6-CBT-sessions for weight loss
Arm Title
2
Arm Type
Experimental
Arm Description
Single educational intervention for weight
Intervention Type
Behavioral
Intervention Name(s)
CBT
Intervention Description
6-CBT based sesions
Intervention Type
Other
Intervention Name(s)
educational
Intervention Description
subjects receive one hour of nutrition education and 5 weekly phone calls
Primary Outcome Measure Information:
Title
The accessibility to overweight outpatients with stable psychotic or mood disorders, currently treated with atypical antipsychotics willing to participate in a research study involving CBT.
Time Frame
3 months
Secondary Outcome Measure Information:
Title
Measure outcome parameters; body mass index, total cholesterol, low-density lipoproteins, triglycerides, fasting blood sugar, waist circumference, blood pressure & pulse among patients receiving CBT treatment or usual care at baseline, 6 wks & 12 wks.
Time Frame
3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years and above Patients with diagnosis of schizophrenia, schizoaffective disorder or bipolar disorder determined by assessment with chart review, currently taking at least one atypical antipsychotic, started at least 2 months prior to randomization Body Mass Index (BMI) greater than 30 ability to consent to treatment, determined by the patient's treating/referring physician Exclusion Criteria: Patients with premorbid medical problems that preclude involvement in a weight loss program Active substance abuse or dependence, indicated by a positive urine drug screen in the last 3 months Mini- Mental Status Exam (MMSE) less than 24 active psychosis or mania, determined by administration of the PANSS score greater than 3 on the following items; delusions, conceptual disorganization, hallucinatory behavior, blunted affect, social withdrawal, lack of spontaneity and conversation flow, mannerisms and posturing, and unusual thought content, and YMRS greater than 10, respectively active major depressive episode, determined by administration of HAM-D greater than 13 patients taking any medications for weight loss or currently enrolled in a weight loss program changes in medication regimen for diabetes or dyslipidemia within the last 3 months
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Rayan Aljurdi, MD
Organizational Affiliation
Michael E. DeBakey VA Medical Center (152)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Michael E. DeBakey VA Medical Center (152)
City
Houston
State/Province
Texas
ZIP/Postal Code
77030
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Cognitive Behavioral Therapy for Obesity

We'll reach out to this number within 24 hrs